Curatis Holding AG (CURN.SW) Stock

CURN.SW logo

Curatis Holding AG

CURN.SWSwitzerland
Healthcare

Company profile

Curatis Holding reported revenue of 10.80 million CHF for fiscal year 2025, up 56.6% from fiscal year 2024. Curatis Holding reports about 9 full-time employees.

What stands out

  • It reported a net loss in each of its last 5 fiscal years; the loss narrowed from 4.35 million CHF in fiscal year 2024 to 1.42 million CHF in fiscal year 2025.
  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Curatis Holding AG

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collagen sponge, benign prostatic hyperplasia, immunomodulator, epilepsy and essential tremor, thyreostatic, hereditary tyrosinemia type 1, nootropic, tranquilizer, helicobacter pylori test, phosphate binder, special nutrition for dialysis patients, dermato corticosteroid, lead and mercury poisoning, corticostimulin, anti-fog agent, chorea associated with huntington's disease, and antiepileptic. The company also develops C-PTBE-01, which is in Phase IIb clinical trial for the treatment of peritumoral brain edema; C-AM-01 that is in Phase IIa clinical trial for the prevention of severe migraine with aura; C-MOH-01, which is in Phase IIa clinical trial for the treatment and prevention of medication overuse headache; and C-FI-01 that is in phase I clinical trial for the treatment of fibrotic or inflammatory orphan or ultra-orphan diseases. The company was founded in 2002 and is based in Liestal, Switzerland.

Leadership

  • Roland Rutschmann — CEO & Executive Director, 63
  • Patrick Ramsauer — Chief Financial Officer
  • Francois Bersier — Chief Operating Officer
  • Gunter Graubach — Founder, Executive Director & Chief Corporate Development Officer, 61
  • Kirsty Crame M.D. — Chief Medical Officer

How much revenue does Curatis Holding make?

Curatis Holding reported 10.80 million CHF in revenue for fiscal year 2025, up 56.6% from 6.90 million CHF in fiscal year 2024.

What companies are similar to Curatis Holding?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Sandoz Group AG (SDZ.SW).

Has Curatis Holding made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 143,000 CHF; FY2022, a loss of 34.73 million CHF; FY2023, a loss of 49.38 million CHF; FY2024, a loss of 4.35 million CHF; FY2025, a loss of 1.42 million CHF. It reported a net loss in each of these 5 years.

How has Curatis Holding's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 0 CHF; FY2022, 0 CHF; FY2023, 0 CHF; FY2024, 6.90 million CHF; FY2025, 10.80 million CHF.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees9
HeadquartersLiestal, Switzerland
ExchangeSwiss
TimezoneEurope/Zurich (CET)

Contact & Links

Address
Weierweg 7, Liestal, 4410
Phone
41 61 927 8777
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Curatis Holding AG (CURN.SW)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/CURN.SW

LinkedInLinkedInXXYouTubeYouTube